BioAtla (BCAB) Revenue & Revenue Breakdown
BioAtla Revenue Highlights
0
Latest Revenue (Q)
$11.00M
BioAtla Revenue by Period
BioAtla Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $250.00K | -41.72% |
| 2020-12-31 | $429.00K | -91.75% |
| 2019-12-31 | $5.20M | -51.07% |
| 2018-12-31 | $10.63M | - |
BioAtla generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
BioAtla Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $11.00M | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.71M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $250.00K | 66.67% |
| 2021-09-30 | $150.00K | -40.00% |
| 2021-06-30 | $250.00K | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2020-09-30 | $150.00K | -21.05% |
| 2020-06-30 | $190.00K | 113.48% |
| 2020-03-31 | $89.00K | -95.96% |
| 2019-12-31 | $2.20M | - |
BioAtla generated $11.00M in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
BioAtla Revenue Breakdown
BioAtla Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Jun 21 |
|---|---|
| Service | $300.00K |
Latest
BioAtla's latest quarterly revenue breakdown by segment (product or service), as of Jun 21: Service (100.00%).
BioAtla Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Jun 21 |
|---|---|
| Service | $300.00K |
Latest
BioAtla's latest quarterly revenue breakdown by geography, as of Jun 21: Service (100.00%).
BioAtla Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KYMR | Kymera Therapeutics | $78.59M | $3.74M |
| NRIX | Nurix Therapeutics | $76.99M | $12.59M |
| FHTX | Foghorn Therapeutics | $34.16M | $7.81M |
| ADAG | Adagene | $18.11M | $833.34K |
| IKNA | Ikena Oncology | $9.16M | - |
| IPSC | Century Therapeutics | $2.23M | $791.00K |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| DSGN | Design Therapeutics | - | - |
| RZLT | Rezolute | - | - |
| CCCC | C4 Therapeutics | - | - |
| ANTX | AN2 Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| BCAB | BioAtla | - | $11.00M |
| AVTE | Aerovate Therapeutics | - | - |
| OLMA | Olema Pharmaceuticals | - | - |
| ERAS | Erasca | - | - |
| PASG | Passage Bio | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| NAUT | Nautilus Bio | - | - |